Carini C, et al. - In this work, researchers investigated if differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from early rheumatoid arthritis (RA) patients before methotrexate (MTX) treatment could assist in identifying non-response to DMARD and, if there is an association between such a signature and RA specific expression quantitative trait loci (eQTL). As per findings, in early RA, detection of a CCS in blood could predict inadequate response to MTX with a high degree of accuracy. Findings thereby confirmed the possibility for a priori stratification of response to MTX, offering a mechanism to provide alternative treatments for non-responders to MTX earlier in the course of the disease.